Table 5.
Targets of clinical stage T-cell redirected therapeutics, TRBAs and CARs *,**.
| Primary Target | Primary Indications | Therapeutic Format | Total | ||
|---|---|---|---|---|---|
| TRBAs | CAR-T/NKs | rCells Expressing FcγRIIIa | |||
| CD19 | B-cell cancer (NHL, etc.) | 2 | 88 | 0 | 90 |
| BCMA | MM | 7 | 26 | 1 | 34 |
| CD123 | AML | 5 | 8 | 0 | 13 |
| Mesothelin | Solid tumors | 1 | 12 | 0 | 13 |
| GD2 | Solid and neurological tumors | 2 | 10 | 0 | 12 |
| CD20 | B-cell cancer (NHL, etc.) | 5 | 4 | 2 | 11 |
| CD33 | AML | 6 | 4 | 0 | 10 |
| HER2 | Solid tumors | 3 | 6 | 0 | 9 |
| CD22 | B-cell cancer (NHL, etc.) | 0 | 8 | 0 | 8 |
| CD30 | HL | 1 | 5 | 6 | |
| PSMA | Solid tumor (prostate) | 4 | 2 | 0 | 6 |
| EGFRvIII | Neurological tumors | 2 | 4 | 0 | 6 |
| EGFR | Solid tumors | 1 | 3 | 0 | 4 |
| CD38 | MM | 2 | 2 | 0 | 4 |
| EpCAM | Solid tumors | 2 | 2 | 0 | 4 |
| PSCA | Solid tumor (prostate) | 1 | 3 | 0 | 4 |
| CEA (CEACAM5) | Solid tumors | 2 | 1 | 0 | 3 |
| HIV | Virus | 1 | 1 | 0 | 2 |
| Glypican-3 | Solid tumors | 1 | 1 | 0 | 2 |
| Flt3 | AML | 1 | 1 | 0 | 2 |
| NKG2D ligands | Solid tumors | 0 | 2 | 0 | 2 |
| Claudin 18.2 | Solid tumors | 0 | 2 | 0 | 2 |
| DLL3 | SCLC | 1 | 1 | 0 | 2 |
| CS1 (SLAMF7) | MM | 0 | 2 | 0 | 2 |
| MUC16 | Solid tumors | 1 | 1 | 0 | 2 |
| Lewis-Y | Solid tumors | 0 | 2 | 0 | 2 |
| cMet | Solid tumors | 0 | 2 | 0 | 2 |
| Others with single candidate | Mostly solid tumors | 10 | 16 | 0 | 26 |
| Undisclosed/other | Unknown | 0 | 6 | 0 | 6 |
| Total | -- | 61 | 225 | 3 | 289 |
* BiStro Biotech Consulting LLC database, locked 20 June 2019. Data obtained from Clinicaltrials.gov, literature papers, company websites, analyst reports and other sources. ** Abbreviations: AML, adult acute myeloid leukemia; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CD, cluster of differentiation; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; EpCAM, epithelial cellular adhesion molecule; GD2, disialoganglioside antigen; HER2, human epidermal growth factor receptor; HL, Hodgkin’s lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NK, natural killer (cells); NKG2D, natural killer group 2D; PD-L1, programmed death ligand-1; PSCA, prostate stem cell antigen; PSMA, prostate-specific membrane antigen; rCells, recombinant NK or T-cells; SCLC, small cell lung cancer; TRBA, T-cell redirecting bispecific antibody.